Type I insulin-like growth factor receptor as a therapeutic target in cancer

Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGFIR) signaling in many different human cancers. Drugs to disrupt IGFIR function have been developed and are now entering clinical trial. This brief review mill identify key areas to consider as these clinical trials move forward.